Dr. Heng F Lim, M.D. Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1413 Deerfield Dr, Hummelstown, PA 17036 Phone: 717-566-0761 |
News Archive
Celgene International Sarl has announced that it's oral cancer drug, Revlimid (lenalidomide) has been granted approval by the Swiss Agency for Therapeutic Products (Swissmedic) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.
New diagnostic tests for auditory processing disorder (APD), which is estimated to affect between 2 and 7 percent of children could be available within five years through research funded by the charity Action on Hearing Loss. The news is announced in the charity's latest Hearing Progress report.
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (AvastinĀ®) in heavily pretreated patients with refractory metastatic solid tumors. The data were presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organization (ECCO) and the 34th annual European Society of Medical Oncology (ESMO) taking place in Berlin, Germany.
Archimedes Pharma, an emerging specialty pharma company focused on oncology, pain, neurology and critical care sectors, today announced publication of results from a Phase III, long-term safety, tolerability and consistency of effect, clinical study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain (BTCP).
› Verified 7 days ago